Jamjoom Pharma to Acquire Pfizer Manufacturing Site in Saudi Arabia

By AI, Created 11:37 AM UTC, May 20, 2026, /AGP/ – Jamjoom Pharma has signed an agreement to buy a pharmaceutical manufacturing facility in King Abdullah Economic City from Pfizer Saudi Limited Company. The deal could expand local production capacity in Saudi Arabia and strengthen supply resilience across the Middle East and Africa, pending regulatory approvals.

Why it matters: - The acquisition would expand Jamjoom Pharma’s manufacturing footprint in Saudi Arabia and support the company’s push to localize production. - The facility could strengthen regional supply resilience and broaden access to affordable healthcare products across the Middle East and Africa. - The deal also aligns with Saudi Arabia’s industrial development and localization priorities.

What happened: - Jamjoom Pharma signed a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility in King Abdullah Economic City, Saudi Arabia. - The announcement was made on April 28, 2026. - The facility specializes in manufacturing and packaging oral solid dosage pharmaceutical products.

The details: - The site operates across the full production chain. - On-site quality control laboratories support the facility’s operations. - Jamjoom Pharma said the site is an important addition to its manufacturing network and is expected to improve production and operational capabilities. - The company said the transaction reflects its long-term growth strategy and commitment to advancing local manufacturing in the Kingdom. - Jamjoom Pharma said the acquisition supports its core value of “Quality Without Compromise.” - The company also said it wants to support workforce stability and build on employees’ established capabilities. - CEO Tarek Hosni said the agreement marks an important milestone in the company’s growth journey and reflects a focus on scalable manufacturing with high standards of quality and operational excellence.

Between the lines: - The purchase gives Jamjoom Pharma a ready-made manufacturing base rather than a greenfield buildout, which can speed up capacity expansion if the transaction closes. - The emphasis on quality standards and workforce continuity suggests the company is trying to preserve operating know-how while integrating the new site. - The deal supports Jamjoom Pharma’s stated goal of becoming a leading healthcare organization across MEA by 2030.

What’s next: - Completion of the transaction still depends on customary closing conditions, including required regulatory approvals. - Jamjoom Pharma said it will announce material developments related to the transaction in line with applicable regulatory requirements. - The company did not disclose financial terms in the announcement.

The bottom line: - If approved, the acquisition could give Jamjoom Pharma a bigger local manufacturing platform and a stronger role in Saudi Arabia’s healthcare industrial base.

For more information, click here